Sonoma Pharmaceuticals (SNOA) Income from Continuing Operations (2010 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Income from Continuing Operations came in at 581000.0 in Q1 2026, up 25.13% year-on-year from 464321.32 in Q1 2025, and up 29.06% quarter-over-quarter from 819000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 581000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 25.13% year-over-year to 581000.0 in Q1 2026; TTM through Mar 2026 was 3175000.0, a 8.16% increase from a year earlier, with the FY2026 full-year figure at 3175000.0, up 8.16% from the prior year.
- Income from Continuing Operations improved to 581000.0 in Q1 2026 per SNOA's latest filing, from 819000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 534000.0 in Q3 2025 and bottomed at 3753000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 1017000.0 (2022), against an average of 1198294.12.
- Across the five-year window, Income from Continuing Operations sank 917.0% in 2022 and soared 65.15% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 1939000.0 in 2022, then jumped by 55.34% to 866000.0 in 2023, then decreased by 7.16% to 928000.0 in 2024, then increased by 11.75% to 819000.0 in 2025, then rose by 29.06% to 581000.0 in 2026.
- Per Business Quant, the three latest SNOA Income from Continuing Operations figures stand at 581000.0 (Q1 2026), 819000.0 (Q4 2025), and 534000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | -581,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -581,000.00 |
| Dec 31, 2025 | -819,000.00 |
| Sep 30, 2025 | -534,000.00 |
| Jun 30, 2025 | -1.24 Mn |
| Mar 31, 2025 | -776,000.00 |
| Dec 31, 2024 | -928,000.00 |
| Sep 30, 2024 | -610,000.00 |
| Jun 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.07 Mn |
| Dec 31, 2023 | -866,000.00 |
| Sep 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | -1.42 Mn |
| Mar 31, 2023 | -1.31 Mn |
| Dec 31, 2022 | -1.94 Mn |
| Sep 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -887,000.00 |
| Mar 31, 2022 | -3.75 Mn |
| Dec 31, 2021 | -944,000.00 |
| Sep 30, 2021 | -100,000.00 |
| Jun 30, 2021 | -1.10 Mn |